PATENT CLAIM ANALYSIS

Application Number: 16228084
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "139100"]

Abstract:
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.

Claim (Index 14):
The antibody of  claim 1 , wherein: (a) the antibody comprises a variable heavy chain (V H ) region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, or 113, and/or a variable light chain (V L ) region comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, or 114; or (b) the antibody comprises a variable heavy chain (V H ) region comprising the amino acid sequence of SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, or 113, and/or a variable light chain (V L ) region comprising the amino acid sequence of SEQ ID NO: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, or 114.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15696972', '15451275', '15545871', '15451280', '12906041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7420222913858292
- 35 USC 102 Novelty (BERT): 0.5356786729306335
- Combined Prediction Score: 0.7213879295403097
- Mean Citation Score: 367.832702
- Max Citation Score: 375.92844
- Similarity Product: 303.2743309142447

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test